Selective killing of tumor cells by xanthates.
Xanthate derivatives of primary alcohols with antiviral properties exert, in combination with monocarboxylic C11 or C12 acids a pronounced anti-tumor activity in vitro and in vivo. Tricyclodecan-9-yl-xanthogenate (D609) or cyclododecyl xanthogenate (D435) when administered together with either undecanoic or dodecanoic acid to various transformed animal and human tumor cells (displaying low serum requirement) cause cell death. In contrast, normal cells from which transformed derivatives arose, were unaffected.
D000818:Animals; D000970:Antineoplastic Agents; D000998:Antiviral Agents / Q000494:pharmacology*; D001952:Bridged-Ring Compounds / Q000494:pharmacology*; D002264:Carboxylic Acids / Q000494:pharmacology; D002460:Cell Line; D002470:Cell Survival / Q000187:drug effects; D002472:Cell Transformation, Viral / Q000187:drug effects; D004357:Drug Synergism; D006801:Humans; D006863:Hydrogen-Ion Concentration; D008214:Lymphocytes / Q000187:drug effects; D009636:Norbornanes; D013859:Thiocarbamates; D013871:Thiones / Q000494:pharmacology*
D000970:Antineoplastic Agents; D000998:Antiviral Agents; D001952:Bridged-Ring Compounds; D002264:Carboxylic Acids; D009636:Norbornanes; D013859:Thiocarbamates; D013871:Thiones; C053000:cyclodecyl xanthogenate; C046498:tricyclodecane-9-yl-xanthogenate